CD40LG and Respiratory tract infection: Significant reductions in the annual rate of respiratory tract infections and serum IgM levels were observed in leniolisib-treated individuals versus standard of care, consistent across all sensitivity analyses, highlighting the potential for leniolisib to deliver long-term benefits.